Globus Medical’s Q2 2026: Margin Lift, Non-GAAP EPS Surge, and a Steady Revenue Path

Quarterly snapshot

• Worldwide net sales: $789.6 million, up 5.9% year over year (5.6% on a constant currency basis).
• GAAP net income: $151.6 million.
• GAAP diluted EPS: $1.10, down 26.2% versus the prior-year quarter—largely a function of a large bargain purchase gain recognized in the year-ago period tied to the Nevro acquisition.
• Non-GAAP diluted EPS: $1.34, up 55.8% from $0.86 in Q2 2025.
• Growth mix: 6% overall quarterly revenue growth; excluding Nevro, growth runs closer to 9%.
• Segment detail: US Spine grew 7%; International Spine grew 14% as-reported and 12% on a constant-currency basis.
• Margin progress: adjusted gross margin expanded roughly 200 basis points versus the prior year.

The accounting backdrop and what it means for apples-to-apples comparisons

The GAAP EPS figure is distorted by a one-off gain in the prior year quarter stemming from the Nevro-related bargain purchase, which makes the year-over-year GAAP comparison non-comparable on a clean basis. The non-GAAP metric, which excludes items like amortization and M&A-related costs, shows a more constructive earnings trajectory. In other words, if you’re measuring progress by earnings power, the non-GAAP line tells a more resilient story than the GAAP line. This is the kind of nuance that can make an “earnings surprise” label wobble when you’re listening to EPS consensus vs. actual results.

Management emphasizes margin expansion and operating leverage as drivers behind the improved non-GAAP EPS, with a note on synergy realization from acquisitions continuing to support profitability on the non-GAAP framework.

Guidance and outlook

The company reaffirmed its full-year 2026 revenue forecast of $3.18 billion to $3.22 billion, and updated its non-GAAP fully diluted EPS target to a range of $4.95 to $5.05 (versus the prior range of $4.70 to $4.80). This combination suggests the operating leverage embedded in the portfolio, plus ongoing efficiency work, should support a steady beat on profitability even as revenue grows in the mid-single digits.

Conference call logistics were noted: Globus Medical will host a teleconference at 4:30 p.m. ET, with live webcast access via the Investor page. The forward-looking tone leans on continued product portfolio depth, exclusive selling channels, and a focused push across US and international spine markets.

What this might portend for GMED and sector peers

The quarterly mix underscores a few durable themes for the spine-and-orthopedics space. First, a robust US Spine takeaway—7% growth—alongside a double-digit international spine contribution on a reported basis signals that demand for Globus Medical’s backbone—pardon the pun—remains resilient beyond the domestic market. If the international spine growth persists on a constant-currency basis, that bodes well for peers with broader global franchises.

Second, non-GAAP EPS momentum matters more than the GAAP floor this quarter. The 55.8% rise in non-GAAP EPS reflects not just top-line strength but mix-driven margin expansion and disciplined cost management. For sector peers, this underscores the payoff of leveraging scale, improving gross margins, and extracting efficiency gains even when reported GAAP earnings get noise from one-time items.

Third, the Nevro-related bargain purchase gain in the prior year remains a reminder that comparability is tricky when acquisitions drive the base. Investors should watch for how much of the non-GAAP uptick is sustainable organically versus the tailwinds from strategic acquisitions that yield synergy and cross-sell opportunities. In the near term, this could influence how earnings surprises are interpreted across the sector—consensus models may need to tilt toward non-GAAP metrics to reflect underlying operating strength.

Finally, the reaffirmed revenue forecast and EPS path suggest the company sees continued solid demand for its spine portfolio, with margin resilience supporting a constructive long-horizon view. For peers, the message is clear: if you can sustain growth in US spine while responsibly expanding margins, you may earn a more favorable multiple even as the sector navigates currency headwinds and competitive dynamics.

Conclusion

Globus Medical’s Q2 2026 results showcase a narrative of resilience: top-line progress is steady, non-GAAP earnings power is clearly improving, and the guidance remains supportive of continued profitability in 2026. While GAAP EPS optics are dimmed by a one-off in the prior year, the underlying earnings engine—driven by US and international spine demand, margin expansion, and disciplined cost control—points to a cash-positive path for the company and a stern reminder to competitors that the spine market still rewards execution. For investors tracking GMED and its peers, the key metrics to watch next are the ongoing trajectory of non-GAAP EPS, the durability of gross-margin gains, and how much of the revenue growth translates into expanded cash returns over the balance of the year.